KRAS and familial pancreatic carcinoma: For instance, silencing KRAS mutations using siRNA has been shown to enhance tumour cell sensitivity to chemotherapeutic agents such as gemcitabine, leading to reduced tumour progression in pancreatic cancer models [61].